Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE ...

"These cells' maturation is arrested in the embryonic stage, even when they've grown in a dish for a year or more," says Chulan Kwon, Ph.D. , an assistant professor of medicine and member of the ...

Short-term IF boosts glucose homeostasis, but prolonged fasting in adolescence may impair β cell maturation—potentially linking chronic IF to type 1 diabetes risk. Study: Chronic intermittent ...

A total of 17 patients were enrolled and received MCARH109 therapy. The maximum tolerated dose was identified at 150×10 6 CAR T cells. At the 450×10 6 CAR T-cell dose, 1 patient had grade 4 ...

So B-cell maturation antigen is an evolving field where we have three ways of targeting this receptor, including the antibody direct conjugate, as well as the chimeric antigen receptor T-cell ...

"We believe we've now found the master switch that drives the maturation process." In the months before and after birth, an infant's heart cells undergo dramatic changes. The cells enlarge ...

Teclistamab is a T-cell–redirecting bispecific antibody that targets B-cell maturation antigen (BCMA). 11,12 In the MajesTEC-1 study, 63% of the patients had a response and 57% remained in ...

While current therapeutic options include chemotherapy and immunotherapy, this study opens new avenues for novel approaches aiming at restoring normal B cell maturation. The team, spearheaded by ...

Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2. This is an ASCO Meeting Abstract ...